Atezolizumab With Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
1. Progression-free survival was 4.1 months in the combination arm vs 2.2 months in the monotherapy arm with an HR ...
Tag: triple negative breast cancer
Pembrolizumab and carboplatin plus docetaxel treatment regimens may provide options for patients with triple-negative breast cancer who are ineligible for anthracycline-based regimens
1. Overall pathologic complete response to treatment of triple-negative breast cancer with a non-anthracycline regimen was 58% 2. The estimated ...
Cisplatin with Veliparib in BRCA Stratified Metastatic Triple-Negative Breast Cancer
1. There was some progression-free survival benefit in adding veliparib to cisplatin in patients who had homologous recombination DNA repair ...
#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
Click to read this study in Journal of Clinical Oncology.
#VisualAbstract: Sacituzumab govitecan increased survival in metastatic triple-negative breast cancer
1. Sacituzumab govitecan was shown to significantly increase overall survival in previously treated metastatic triple-negative breast cancer patients compared to ...
Sacituzumab govitecan increased survival in metastatic triple-negative breast cancer
1. Sacituzumab govitecan was shown to significantly increase overall survival in previously treated metastatic triple-negative breast cancer patients compared to ...
Clinicopathological heterogeneity in triple-negative breast cancers associated with variable prognosis and therapeutic outcomes
1. Heterogeneity in histological profile linked to improved overall survival, chemotherapy response, and clinical course despite triple-negative receptor status in ...
#VisualAbstract: Chemotherapy in addition to local therapy may improve overall survival in patients aged 70 years or older with triple-negative breast cancer
Click to read the study in The Lancet Oncology
#VisualAbstract: Pembrolizumab plus chemotherapy improves survival in patients with metastatic triple-negative breast cancer
1. First line treatment with pembrolizumab-chemotherapy showed significant improvement in progression-free survival compared to chemotherapy alone in patients with metastatic ...
